Odanacatib in postmenopausal women with low bone mineral density: a review of current clinical evidence

Odanacatib in the treatment of postmenopausal women with low bone mineral density: Five years of continued therapy in a phase 2 study

(2012) Bente Langdahl et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Effects of ONO-5334, a novel orally-active inhibitor of cathepsin K, on bone metabolism

(2011) Yasuo Ochi et al.   BONE

The effects of the cathepsin K inhibitor odanacatib on osteoclastic bone resorption and vesicular trafficking

(2011) P. Leung et al.   BONE

Pharmacokinetics and Metabolism in Rats, Dogs, and Monkeys of the Cathepsin K Inhibitor Odanacatib: Demethylation of a Methylsulfonyl Moiety as a Major Metabolic Pathway

(2011) K. Kassahun et al.   DRUG METABOLISM AND DISPOSITION

Glucocorticoid dose determines osteocyte cell fate

(2011) Junjing Jia et al.   FASEB JOURNAL

Safety and efficacy of the cathepsin K inhibitor ONO-5334 in postmenopausal osteoporosis: The OCEAN study

(2011) Richard Eastell et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Odanacatib reduces bone turnover and increases bone mass in the lumbar spine of skeletally mature ovariectomized rhesus monkeys

(2011) Patricia J Masarachia et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Effects of Denosumab Treatment and Discontinuation on Bone Mineral Density and Bone Turnover Markers in Postmenopausal Women with Low Bone Mass

(2011) Henry G. Bone et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Morphea-like skin reactions in patients treated with the cathepsin K inhibitor balicatib

(2011) Thomas M. Rnger et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Cathepsin K: its skeletal actions and role as a therapeutic target in osteoporosis

(2011) Aline G. Costa et al.   Nature Reviews Rheumatology

Balicatib, a cathepsin K inhibitor, stimulates periosteal bone formation in monkeys

(2011) C. Jerome et al.   OSTEOPOROSIS INTERNATIONAL

Denosumab and bisphosphonates: Different mechanisms of action and effects

(2010) Roland Baron et al.   BONE

Future of anticathepsin K drugs: dual therapy for skeletal disease and atherosclerosis?

(2010) Izabela Podgorski   Future Medicinal Chemistry

Cathepsin K inhibitors prevent bone loss in estrogen-deficient rabbits

(2010) Brenda L Pennypacker et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Odanacatib in the treatment of postmenopausal women with low bone mineral density: Three-year continued therapy and resolution of effect

(2010) John A Eisman et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Osteoporosis: impact on health and economics

(2010) Nicholas Harvey et al.   Nature Reviews Rheumatology

Pharmacological inhibitors to identify roles of cathepsin K in cell-based studies: a comparison of available tools

(2009) Sylvie Desmarais et al.   BIOLOGICAL CHEMISTRY

The discovery of MK-0674, an orally bioavailable cathepsin K inhibitor

(2009) Elise Isabel et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Treatment with a Potent Cathepsin K Inhibitor Preserves Cortical and Trabecular Bone Mass in Ovariectomized Monkeys

(2009) G. B. Stroup et al.   CALCIFIED TISSUE INTERNATIONAL

Effect of the Cathepsin K Inhibitor Odanacatib on Bone Resorption Biomarkers in Healthy Postmenopausal Women: Two Double-Blind, Randomized, Placebo-Controlled Phase I Studies

(2009) S A Stoch et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Identification of NFAT binding sites that mediate stimulation of cathepsin K promoter activity by RANK ligand

(2009) Wayne Balkan et al.   GENE

Of mice and men: divergent risks of teriparatide-induced osteosarcoma

(2009) V. Subbiah et al.   OSTEOPOROSIS INTERNATIONAL

The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K

(2008) Jacques Yves Gauthier et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Bone density, strength, and formation in adult cathepsin K (−/−) mice

(2008) B. Pennypacker et al.   BONE

Cathepsin K inhibitors prevent matrix-derived growth factor degradation by human osteoclasts

(2007) Karen Fuller et al.   BONE